Similar articles

• Adding metformin to insulin did not improve a composite of microvascular and macrovascular disease in type 2 diabetes.

  Fonseca V. Fonseca V. Evid Based Med. 2009 Oct;14(5):139. doi: 10.1136/ebm.14.5.139. Evid Based Med. 2009. PMID: 19794014 No abstract available.
• ACP Journal Club. Intensive glucose control did not reduce a composite of microvascular events more than standard control in type 2 diabetes.

  Aron DC, Pogach LM. Aron DC, et al. Ann Intern Med. 2010 Nov 16;153(10):JC5-9. doi: 10.7326/0003-4819-153-10-201011160-02009. Ann Intern Med. 2010. PMID: 21079216 No abstract available.
• ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes.

  Lipscombe L. Lipscombe L. Ann Intern Med. 2009 Apr 21;150(8):JC4-8. doi: 10.7326/0003-4819-150-8-200904210-02008. Ann Intern Med. 2009. PMID: 19391221 No abstract available.
• Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes.

  Lebovitz HE. Lebovitz HE. Diabetes Care. 1999 Apr;22 Suppl 3:C41-4. Diabetes Care. 1999. PMID: 10189561 Review.
• Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?

  Rensing KL, Reuwer AQ, Arsenault BJ, von der Thüsen JH, Hoekstra JB, Kastelein JJ, Twickler TB. Rensing KL, et al. Diabetes Obes Metab. 2011 Dec;13(12):1073-87. doi: 10.1111/j.1463-1326.2011.01468.x. Diabetes Obes Metab. 2011. PMID: 21736687 Review.